Technology | Drug-Eluting Balloons | September 19, 2016

Medtronic IN.PACT Admiral Drug-Coated Balloon Approved for Treatment of In-stent Restenosis

Expanded FDA indication makes IN.PACT Admiral the first DCB approved to treat ISR

Medtronic, IN.PACT Admiral drug-coated balloon, DCB, FDA approval, in-stent restenosis, ISR

September 19, 2016 — Medtronic plc announced that the U.S. Food and Drug Administration (FDA) approved the IN.PACT Admiral drug-coated balloon (DCB) as a treatment for in-stent restenosis (ISR) in patients with peripheral artery disease (PAD). This is the first DCB that has gained approval to treat ISR in the United States. FDA approval was based on ISR data from the IN.PACT Global Study compared to a standard percutaneous balloon angioplasty (PTA) control.

"We are experiencing a paradigm shift in treating patients with complex PAD," said John Laird, M.D., interventional cardiologist at U.C. Davis Medical Center and co-principal investigator for the IN.PACT SFA Trial. "Until now physicians have had limited treatment options to address patients with ISR. The FDA's approval of IN.PACT Admiral DCB allows us to treat patients with a durable, proven and safe technology."

ISR occurs when a stent is placed in the artery to restore blood flow but over time plaque can form in and around the stent. This condition is estimated to occur in up to 40 percent of all stents placed in the superficial femoral artery (SFA).

Real-world data from the IN.PACT Global Study demonstrating safe and effective treatment of complex ISR lesions was first presented on the scientific podium at VIVA 2015. The one-year primary patency rate for this difficult-to-treat patient subgroup in the IN.PACT Global ISR Imaging Cohort was 88.7 percent, and the clinically-driven target revascularization (CD-TLR) rate was 7.3 percent. The mean length of lesions was 17.2 ± 10.5 cm, with 34.0 percent occluded ISR lesions. Additional ISR data from the IN.PACT Global Study and a PTA control were used to gain FDA approval of the ISR indication.

The IN.PACT Admiral drug-coated balloon is a clinically-proven, cost-effective primary endovascular therapy that enables physicians to treat claudication and restenosis for patients with superficial femoral artery (SFA) disease. The DCB's primary mode of action is physical dilatation of the vessel lumen by PTA, and the proven paclitaxel drug is intended to prevent artery narrowing by minimizing scar tissue formation.

IN.PACT Admiral DCB received the CE Mark in 2009 to treat PAD and was approved by the FDA in December 2014 to treat superficial femoral and popliteal arteries.

For more information: www.medtronic.com

Related Content

News | Drug-Eluting Balloons

June 8, 2022 — The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial ...

Home June 08, 2022
Home
News | Drug-Eluting Balloons

May 27, 2022 — Medtronic today announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 ...

Home May 27, 2022
Home
News | Drug-Eluting Balloons

May 27, 2022 — The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a ...

Home May 27, 2022
Home
News | Drug-Eluting Balloons

March 31, 2022 — In accordance with its commitment to patient safety, Medtronic recently voluntarily recalled a subset ...

Home March 31, 2022
Home
News | Drug-Eluting Balloons

November 10, 2021 — Biosensors International Group Ltd., a developer and manufacturer of innovative medical devices ...

Home November 10, 2021
Home
News | Drug-Eluting Balloons

October 20, 2021 — 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a late-breaking ...

Home October 20, 2021
Home
News | Drug-Eluting Balloons

March 12, 2021 — Philips Healthcare announced the final, five-year results of two major randomized controlled trials ...

Home March 12, 2021
Home
News | Drug-Eluting Balloons

November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated ...

Home November 03, 2020
Home
News | Drug-Eluting Balloons

October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the ...

Home October 18, 2020
Home
Videos | Drug-Eluting Balloons

Juan F. Granada, M.D., CEO of the Cardiovascular Research Foundation (CRF) worked on preclinical development work for a ...

Home September 09, 2020
Home
Subscribe Now